•   George Lundberg, MD

    In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    The most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.

    .

  •   George Lundberg, MD

    Cancer that spreads to the brain is very difficult to treat, especially because of the blood-brain barrier. This article from The ASCO Post describes one promising new treatment.

    .

  •  

    How an Emory Professor would Treat Her Own Advanced Endometrial Cancer

    With: Jane Meisel, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Jane Meisel, MD, how she would handle her own advanced endometrial cancer. Dr. Meisel is Associate Professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University in Atlanta, GA. Curious Dr. George: Please consider a hypothetical… Read more »

  •   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

    .

  •   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  •   George Lundberg, MD

    Published by Targeted Therapies in Oncology for healthcare professionals, this article outlines how novel targeted therapies have largely replaced chemotherapy and prolonged life greatly for people with chronic lymphocytic leukemia (CLL).

    .

  •   George Lundberg, MD

    Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.

    .

  •   George Lundberg, MD

    Read about personalized and targeted treatments for many types of lymphoma in this scientific review paper written for medical and research professionals and published in the Journal of Clinical Medicine.

    .

    .

  •   George Lundberg, MD

    According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.

    .